Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5648402 | 0.93 | RIPK1 (0.38) | RIPK1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL5647255 | 0.87 | RIPK1 (0.41) | RIPK1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL25242302 | 0.85 | RIPK1 (0.39) | RIPK1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL3754160 | 0.84 | KCNA5 (0.41) | RIPK1LMNA | |
| SCHEMBL25242324 | 0.81 | RIPK1 (0.37) | RIPK1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL25290263 | 0.81 | RIPK1 (0.37) | RIPK1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL25286462 | 0.80 | RIPK1 (0.36) | RIPK1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL25286605 | 0.78 | RIPK1 (0.34) | RIPK1SLC6A2SLC6A4GRM5 | |
| SCHEMBL1438626 | 0.73 | RIPK1 (0.41) | RIPK1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL2518702 | 0.72 | RIPK1 (0.40) | RIPK1MEN1KMT2AHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161643-A1 | Pyridin-2-one compounds useful as inhibitors of thrombin | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161643-A1 | Pyridin-2-one compounds useful as inhibitors of thrombin | PLG, F2, PLAT | RIPK1 1086/4885MEN1 1252/4885KMT2A 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.